1989 FASEB CONFERENCE--BIOLOGY AND CHEMISTRY OF VISION

我们请求资金帮助支持1989年的FASE B夏季会议 视觉生物学和化学研究会议。这个 会议将于1989年6月25日至30日在佛蒙特州学院举行， 佛蒙特州萨克斯顿河。会议的目标有三个：1) 总结当前研究进展并开发新的攻击方法 关于视觉的分子机制，2)吸引和定向新的 研究人员到现场，3)将新的分子发现联系起来 对致盲视网膜疾病的发病机制和治疗有一定的指导意义。 与戈登会议一样，FASEB的会议形式是 非同寻常地有利于富有成果的讨论。会议将于 规模较小(约165人)，并将在隔离的 佛蒙特州乡村的环境。将有时间进行深入的调查 这种讨论在较大的会议上是很少见的。这个 会议将是跨学科的，并将涉及分子 生物学家，细胞生物学家，生物物理学家，临床医生， 生物化学家和电生理学家。 会议的主题将是分子机制。 幻觉。九个上午和晚上的课程将集中在视觉上 光激活的色素、化学和分子生理学 光感受器细胞的酶系统和离子转运蛋白， 光感受器的细胞生物学、分子机制 遗传性视网膜变性、视网膜突触和 无脊椎动物的光传导。下午的海报会议将 使所有参与者都能介绍和讨论他们当前的工作。 将基础科学与 重要的临床问题将由一位杰出的 临床医生兼科学家。这个演讲，连同关于 视网膜退化，应该会导致新的和多产的 基础科学家和临床医生之间的互动。

We request funds to help support a 1989 FASEB Summer Research Conference on The Biology and Chemistry of Vision. The meeting will be held June 25 - 30, 1989 at the Vermont Academy, Saxtons River, Vermont. The goal of the meeting is threefold: 1) to summarize current progress and develop new attacks in research on molecular mechanisms of vision, 2) to attract and orient new investigators to the field, 3) to relate new molecular findings to the pathogenesis and treatment of blinding retinal disease. The FASEB meeting format, like that of Gordon conferences, is unusually conducive to fruitful discussion. The meeting will be small (about 165 participants) and will be held in the isolated environment of rural Vermont. Time will be available for in-depth discussions of a kind that are rare at larger meetings. The conference will be interdisciplinary, and will involve molecular biologists, cell biologists, biophysicists, clinicians, biochemists, and electrophysiologists. The theme of the meeting will be Molecular Mechanisms of Vision. Nine morning and evening sessions will focus on visual pigments, chemistry and molecular physiology of the light activated enzyme systems and ion transport proteins of photoreceptor cells, the cell biology of photoreceptors, molecular mechanisms of hereditary retinal degenerations, retinal synapses, and phototransduction in invertebrates. Afternoon poster sessions will enable all participants to present and discuss their current work. A special keynote address that relates basic science to an important clinical problem will be given by a distinguished clinician-scientist. This talk, together with the session on retinal degenerations, should lead to new and productive interactions between basic scientists and clinicians.